XYL-1 is a highly potent inhibitor of PARP7 with and IC50 of 0.6 nM. It could enhance the type-Ⅰinterferon signaling in vitro, and can be a potential candidate for developing cancer immunotherapy agents.

XYL-1 is a highly potent inhibitor of PARP7 with and IC50 of 0.6 nM. It could enhance the type-Ⅰinterferon signaling in vitro, and can be a potential candidate for developing cancer immunotherapy agents.

XYL-1 is a highly potent inhibitor of PARP7 with and IC50 of 0.6 nM. It could enhance the type-Ⅰinterferon signaling in vitro, and can be a potential candidate for developing cancer immunotherapy agents.

CP681301 is a highly specific, brain-permeable inhibitor of Cdk5. It exhibits antiproliferative and anti-tumor activity by reducing stem cell marker expression, and cell proliferation in mouse xenografts ex vivo.

CP681301 is a highly specific, brain-permeable inhibitor of Cdk5. It exhibits antiproliferative and anti-tumor activity by reducing stem cell marker expression, and cell proliferation in mouse xenografts ex vivo.

QS11 acts as an inhibitor of ARFGAP1 (ADP-ribosylation factor GTPase-activating protein 1), with an EC50 of 1.5 μM. QS11 regulates Wnt/β-catenin signaling by interacting with ARF GTPase-activating protein 1 (ARFGAP1) and influences protein trafficking. Additionally, QS11 suppresses the migration of breast cancer cells that overexpress ARFGAP1.

QS11 acts as an inhibitor of ARFGAP1 (ADP-ribosylation factor GTPase-activating protein 1), with an EC50 of 1.5 μM. QS11 regulates Wnt/β-catenin signaling by interacting with ARF GTPase-activating protein 1 (ARFGAP1) and influences protein trafficking. Additionally, QS11 suppresses the migration of breast cancer cells that overexpress ARFGAP1.

CP681301 is a highly specific, brain-permeable inhibitor of Cdk5. It exhibits antiproliferative and anti-tumor activity by reducing stem cell marker expression, and cell proliferation in mouse xenografts ex vivo.

CP681301 is a highly specific, brain-permeable inhibitor of Cdk5. It exhibits antiproliferative and anti-tumor activity by reducing stem cell marker expression, and cell proliferation in mouse xenografts ex vivo.

QS11 acts as an inhibitor of ARFGAP1 (ADP-ribosylation factor GTPase-activating protein 1), with an EC50 of 1.5 μM. QS11 regulates Wnt/β-catenin signaling by interacting with ARF GTPase-activating protein 1 (ARFGAP1) and influences protein trafficking. Additionally, QS11 suppresses the migration of breast cancer cells that overexpress ARFGAP1.